Search

Your search keyword '"Département Gastroentérologie"' showing total 22 results
Start Over Author "Département Gastroentérologie"
22 results on '"Département Gastroentérologie"'

1. Anti-TNF Agents Restrict Adherent-invasive Escherichia coli Replication Within Macrophages Through Modulation of Chitinase 3-like 1 in Patients with Crohn’s Disease

Author

Clara Douadi, Emilie Vazeille, Christophe Chambon, Michel Hébraud, Margot Fargeas, Marie Dodel, Dilek Coban, Bruno Pereira, Aurélien Birer, Pierre Sauvanet, Anthony Buisson, Nicolas Barnich, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Qualité des Produits Animaux (QuaPA), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Plateforme Exploration du Métabolisme (PFEM), Institut National de la Recherche Agronomique (INRA)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-MetaboHUB-Clermont, MetaboHUB-MetaboHUB, Microbiologie Environnement Digestif Santé (MEDIS), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), and Département gastroentérologie

Subjects
Proteomics, Macrophages, [SDV]Life Sciences [q-bio], Gastroenterology, Membrane Proteins, anti-TNF, General Medicine, Bacterial Adhesion, Crohn's disease, Crohn Disease, chitinase 3-like 1, Escherichia coli, Humans, Tumor Necrosis Factor Inhibitors, Chitinase-3-Like Protein 1, Intestinal Mucosa, Escherichia coli Infections, AIEC
Abstract

Background and Aims The mechanism of action of anti-tumour necrosis factor [anti-TNF] agents could implicate macrophage modulation in Crohn’s disease [CD]. As CD macrophages are defective in controlling CD-associated adherent-invasive Escherichia coli [AIEC], anti-TNF agents could limit AIEC replication within macrophages. We assessed the effect of anti-TNF agents on AIEC survival within monocyte-derived macrophages [MDMs] from CD patients and attempted to identify the proteins involved. Methods Peripheral blood MDMs were obtained from 44 CD patients [22 with and 22 without anti-TNF agents]. MDMs were infected with reference strain AIEC-LF82. Proteomic analysis was performed before and 6 h after AIEC-LF82 infection. Results AIEC-LF82 survival was lower in MDMs from CD patients receiving anti-TNF agents compared to those who did not [−73%, p = 0.006]. After AIEC-LF82 infection, the levels of CD82 [p = 0.007], ILF3 [Interleukin enhancer-binding factor 3; p = 0.001], FLOT-1 [Flotillin-1; p = 0.007] and CHI3L1 [Chitinase 3-like 1; p = 0.035] proteins were different within CD-MDMs depending on anti-TNF exposure. FLOT-1 [ϱ = −0.44; p = 0.038] and CHI3L1 [ϱ = 0.57, p = 0.006] levels were inversely and positively correlated with AIEC survival within MDMs from CD patients with or without anti-TNF, respectively. We observed a dose-dependent decrease of AIEC-LF82 survival after adjunction of anti-TNF within MDMs, inducing an increase of FLOT-1 and decrease of CHI3L1 mRNA levels. Neutralization of intra-macrophagic CHI3L1 protein using anti-CHI3L1 antibodies reduced AIEC survival within macrophages 6 h after infection [p < 0.05]. Conclusion Anti-TNF agents are able to restrict replication of pathobionts, such as AIEC, within macrophages by modulating FLOT-1 and CHI3L1 expression in CD patients.

Published
2022
Full Text
View/download PDF

2. No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy

Author

Wils, P., Seksik, P., Stefanescu, C., Nancey, S., Allez, M., Laharie, D., de Chambrun, G. Pineton, Altwegg, R., Gilletta, C., Vuitton, L., Viennot, S., Serrero, M., Fumery, Mathurin, Savoye, G., Collins, M., Goutorbe, F., Brixi, H., Bouguen, G., Tavernier, N., Boualit, M., Amiot, A., Abitbol, V., Pariente, B., Grp, Getaid, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Beaujon, Assistance Publique - Hôpitaux de Paris, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Physics, University of Surrey, University of Surrey (UNIS), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Hospitalier de la Côte Basque, CHU Pontchaillou [Rennes], Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada, Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France, Centre hospitalier [Valenciennes, Nord], Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille, and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

3. Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn’s disease

Author

Anthony Buisson, Constance Hordonneau, Marion Goutte, Bruno Pereira, Felix Goutorbe, Gilles Bommelaer, Maud Reymond, C. Allimant, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte - Clermont Auvergne (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Service de Radiologie, Hospices Civils de Lyon (HCL), Département Gastroentérologie, Centre Hospitalier Universitaire Estaing, CHU Clermont-Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Service d’Imagerie Médicale et Radiologie Interventionnelle [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], and CHU Clermont-Ferrand-CHU Clermont-Ferrand

Subjects
Adult, Male, medicine.medical_specialty, Therapeutic target, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, MaRIA, Internal medicine, Post-hoc analysis, medicine, Humans, Prospective Studies, Prospective cohort study, ComputingMilieux_MISCELLANEOUS, Inflammation, Crohn's disease, medicine.diagnostic_test, business.industry, Gastroenterology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Magnetic resonance imaging, Middle Aged, Hepatology, medicine.disease, Magnetic Resonance Imaging, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Colorectal surgery, Clermont score, 3. Good health, Surgery, Clinical trial, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, business, Follow-Up Studies, MRI, Abdominal surgery
Abstract

Endoscopic mucosal healing is considered as the best therapeutic target in Crohn’s disease (CD) as it is associated with better long-term outcomes. We investigated whether bowel wall healing (BWH) assessed using magnetic resonance imaging (MRI) could predict favorable outcomes and could be a potential therapeutic target. We performed a post hoc analysis from two prospective studies (n = 174 patients). All the patients with previous objective signs of bowel inflammation and assessed by MRI for therapeutic efficacy had a standardized and blinded evaluation, and underwent MRI. Complete BWH was defined as no segmental MaRIA > 7 or no segmental Clermont score > 8.4 and BWH as no segmental MaRIA > 11 or no segmental Clermont score > 12.5. Clinical corticosteroid-free remission (CFREM) was defined as no reappearance or worsening of clinical manifestation leading to therapeutic modification, hospitalization or CD-related surgery. Multivariate analyses were performed including all the relevant parameters. Overall, 63 patients with CD were included (mean follow-up = 4.8 ± 3.1 semesters). In multivariate analysis (n = 303 semesters), complete BWH or BWH was associated with sustained CFREM according to MaRIA [OR = 4.42 (2.29–26.54); p = 0.042 and OR = 3.43 (1.02–27.02); p = 0.047, respectively] or Clermont score [OR = 3.09 (1.01–12.91); p = 0.049 and OR = 3.88 (1.40–13.80); p = 0.036, respectively]. In multivariate analysis (n = 63 patients), complete BWH or BWH was associated with decreased risk of surgery using MaRIA [HR = 0.16 (0.043–0.63); p = 0.008 and HR = 0.24 (0.07–0.77); p = 0.017, respectively] or Clermont score [HR = 0.24 (0.07–0.78); p = 0.016 and HR = 0.23 (0.07–0.76); p = 0.016, respectively]. MRI endpoints are predictive of favorable outcomes after medical therapy and could be used as therapeutic target in daily practice and clinical trials.

Published
2018
Full Text
View/download PDF

4. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial

Author

Laurent Peyrin-Biroulet, Stéphane Paul, Anne Berger, Hubert Marotte, N Williet, Jean-Marc Phelip, Gilles Boschetti, Bernard Flourié, Xavier Roblin, Jean-Frederic Colombel, Stéphane Nancey, E. Del Tedesco, Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Autophagie infection et immunité - Autophagy Infection Immunity (APY), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU St Etienne, Laboratoire d'Immunologie, CHU Saint Etienne, Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Département Gastroentérologie New York, Service de Gastro-entérologie et Hépatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Azathioprine, Gastroenterology, Inflammatory bowel disease, law.invention, 0302 clinical medicine, Clinical Protocols, Randomized controlled trial, law, Clinical endpoint, heterocyclic compounds, Pharmacology (medical), Prospective Studies, Middle Aged, 3. Good health, Antirheumatic Agents, 030220 oncology & carcinogenesis, Combination, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.IMM]Life Sciences [q-bio]/Immunology, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Drug, medicine.drug, Adult, medicine.medical_specialty, Combination therapy, Drug Administration Schedule, Dose-Response Relationship, Young Adult, 03 medical and health sciences, Pharmacotherapy, Drug Therapy, Pharmacokinetics, Internal medicine, medicine, Humans, neoplasms, Aged, Dose-Response Relationship, Drug, Hepatology, business.industry, Inflammatory Bowel Diseases, medicine.disease, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Infliximab, Surgery, stomatognathic diseases, business
Abstract

International audience; BACKGROUND: Infliximab (IFX) combined with azathioprine (AZA) is more effective than IFX monotherapy in inflammatory bowel disease (IBD). AIM: To identify the AZA optimal dose that is required for efficacy when receiving combination therapy. METHODS: Patients with IBD in durable remission on combination therapy were enrolled in a 1-year, open-label, prospective trial after randomisation into three groups: AZA steady (2-2.5~mg/kg/day, n=28) vs AZA down (dose was halved 1-1.25~mg/kg/day, n=27) vs AZA stopped (n=26). Primary endpoint was failure defined as occurrence of a clinical relapse and/or any change in IBD therapy. RESULTS: Eighty-one patients were included. Five (17.9%), 3 (11.1%), and 8 (30.8%) patients experienced failure at 1~year in groups AZA steady, AZA down and AZA stopped, respectively (P=.1 across the groups). The median trough levels of IFX at inclusion were close to those measured at the end of follow-up in group AZA steady (3.65 vs 3.45~μg/mL, P=.9) and in group AZA down (3.95 vs 3.60~μg/mL, P=.5), whereas these levels dropped from 4.25 to 2.15~μg/mL (P=.02) in group AZA stopped. Four (14.3%), four (14.8%) and 11 (42.3%) patients experienced an unfavourable evolution of IFX pharmacokinetics in groups AZA steady, AZA down and AZA stopped, respectively. A threshold of 6-TGN \textless105~pmoles/8.108 RBC was associated with an unfavourable evolution of IFX pharmacokinetics. CONCLUSIONS: Under combination therapy, AZA dose reduction, but not withdrawal, appears to be as effective as continuation of AZA at full dose.

Published
2017
Full Text
View/download PDF

5. Efficacy of infliximab after failure of subcutaneous anti-TNF agents in patients with ulcerative colitis: A multicentre study

Author

Streichenberger, A., Benjamin Pariente, Bozon, A., Arab, N., Amiot, A., Vuitton, L., Tilmant, M., Nachury, M., Altwegg, R., Delasalle, T., Gagniere, C., Gregoire, B., Fumery, M., Wils, P., Chambrun, G. P., Hebuterne, X., Pereira, B., Bommelaer, G., Buisson, A., Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Université de Poitiers-Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Département de Gastroentérologie, Hôpital de l'Archet 2, CHU Henri Mondor, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Amiens-Picardie, Unité de Biostatistique, CRLCC René Gauducheau, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de la Recherche Agronomique (INRA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Henri Mondor [Créteil], and Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)

Subjects
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

6. Faecal calprotectin is highly effective to detect endoscopic ulcerations in Crohn's disease regardless of disease location

Author

Buisson, A., Mak, W. Y., Andersen, M. J., Lei, D., Pekow, J., Cohen, R. D., Pereira, B., Rubin, D. T., Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Inflammatory Bowel Disease Center,, Cedars-Sinai Medical Center, Queen Elizabeth Hospital, Unité de Biostatistique, and CRLCC René Gauducheau

Subjects
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

7. Histological activity in Crohn's disease: Relationship with clinical indices, endoscopic activity and faecal calprotectin

Author

Buisson, A., Mak, W. Y., Andersen, M. J., Lei, D., Pekow, J., Cohen, R. D., Pereira, B., Setia, N., Weber, C., Hart, J., Rubin, D. T., Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Inflammatory Bowel Disease Center,, Cedars-Sinai Medical Center, Queen Elizabeth Hospital, CHU Clermont-Ferrand, and University of Chicago Medicine

Subjects
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018
Full Text
View/download PDF

8. Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID

Author

Caron, B., Peyrin-Biroulet, L., Nachury, M., Bouhnik, Y., Seksik, P., Bouguen, G., Caillo, L., Laharie, D., Carbonnel, F., Altwegg, R., Reenaers, C., Serrero, M., Boureille, A., Nancey, S., Filippi, J., Abitbol, V., Savoye, G., Vuitton, L., Viennot, S., Fumery, Mathurin, Reymond, M., Bronowicki, J. P., Reimund, J. -M., Amiot, A., Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Gastroenterology and Hepatology, University Medical Centre, Centre Hospitalier Universitaire de Nice (CHU Nice), Laboratoire GlaxoSmithKline [ Marly-le-Roi], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Departement de Gastroentérologie, Hôpital de Hautepierre [Strasbourg], CHU Henri Mondor [Créteil], Institut des Sciences de la Terre de Paris (iSTeP), Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Hôpital Charles Nicolle [Rouen]-CHU Rouen, CHU Henri Mondor, and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

9. Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic de-escalation in patients with inflammatory bowel diseases

Author

Buisson, A., Mak, W. Y., Andersen, M. J., Lei, D., Kahn, S. A., Pekow, J., Cohen, R. D., Zmeter, N., Pereira, B., Rubin, D. T., Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Queen Elizabeth Hospital, Inflammatory Bowel Disease Center,, Cedars-Sinai Medical Center, Unité de Biostatistique, and CRLCC René Gauducheau

Subjects
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Abstract

International audience; Background The selection of the best patients who may benefit from therapeutic de-escalation (TDE) and how to monitor them is a concern and a clinical challenge in inflammatory bowel diseases (IBD). The role of faecal calprotectin (Fcal) remains poorly investigated in these situations. We aimed to assess Fcal level before TDE as predictor of clinical relapse and to evaluate serial measurements of Fcal to predict clinical relapse after TDE. Methods From a prospectively maintained database, we enrolled all IBD patients in clinical remission, with Fcal measured within 8 weeks before therapeutic de-escalation. TDE was defined as decrease of dose or increase of interval between two infusions/injections or medication discontinuation or replacement by a medication that is traditionally earlier in a “step-up” approach to IBD management (5-ASA < immunosuppressants < biologics). Clinical relapse was defined as reappearance of clinical manifestations (HBI > 4 or SCCAI > 2 with sub-score > 1 for at least one item among stool frequency and rectal bleeding) leading to therapeutic intensification, hospitalisation or IBD-related surgery.

Published
2018

10. Faecal calprotectin as surrogate marker of transmural healing assessed using MRI in patients with Crohn's disease

Author

Allimant, C., Messadeg, L., Quinard, R. Minet, Goutte, Marion, Bouvier, D., Goutorbe, F., Pereira, B., Bommelaer, G., Hordonneau, C., Buisson, A., Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Département de Radiologie (LYON - Radio), CHU Lyon, Laboratoire de Biochimie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Centre Hospitalier de la Côte Basque (CHCB), Unité de Biostatistique, CRLCC René Gauducheau, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), and Centre Hospitalier de la Côte Basque

Subjects
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

11. Comparison between faecal chitinase 3-like 1, matrix metalloprotease 9, and calprotectin to assess mucosal healing in Crohn's disease: a multicentre prospective study

Author

Buisson, A., Fumery, M., Hebuterne, X., Benjamin Pariente, Nancey, S., Quinard, R. M., Peyrin-Biroulet, L., Seksik, P., Allez, M., Lambert, C., Dupas, J. L., Filippi, J., Nachury, M., Boschetti, G., Goutte, M., Pereira, B., Bouvier, D., Bommelaer, G., Barnich, N., Vazeille, E., Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de la Recherche Agronomique (INRA), CHU Amiens-Picardie, Département de Gastroentérologie, Hôpital de l'Archet 2, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Université de Poitiers-Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Laboratoire de Biochimie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hopital Saint-Louis [AP-HP] (AP-HP), Unité de Biostatistique, CRLCC René Gauducheau, Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, and Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)

Subjects
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

12. MRI remission after therapeutic intervention is associated with more time spent in clinical corticosteroids-free remission and decreased risk of surgery in Crohn's disease

Author

Buisson, A., Hordonneau, C., Goutorbe, F., Allimant, C., Goutte, Marion, Reymond, M., Pereira, B., Bommelaer, G., Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Département de Radiologie (LYON - Radio), CHU Lyon, Centre Hospitalier de la Côte Basque (CHCB), Délégation à la Recherche Clinique et à l'Innovation (DRCI), and Centre Hospitalier de la Côte Basque

Subjects
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

13. Definition of therapeutic response criteria using MRI in Crohn's disease patients treated with anti-TNF therapy: a multicenter prospective study (the IRMA study)

Author

Constance Hordonneau, Reimund, Cédric Duron, Bruno Pereira, Jean-Marie, Anne-Laure Boucher, Camille Sautel, Marion Goutte, Gilles Bommelaer, Guillaume Bouguen, Leila Messadeg, Michel Dapoigny, Julien Scanzi, Felix Goutorbe, Anthony Buisson, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Département de Radiologie (LYON - Radio), CHU Lyon, CHU Pontchaillou [Rennes], Centre Hospitalier de la Côte Basque, Departement de Gastroentérologie, Hôpital de Hautepierre [Strasbourg], Hôpital d'Issoire, Partenaires INRAE, Hôpital de Montluçon, Délégation à la Recherche Clinique et à l'Innovation (DRCI), and Centre Hospitalier de la Côte Basque (CHCB)

Subjects
0301 basic medicine, medicine.medical_specialty, Crohn's disease, Hepatology, business.industry, Gastroenterology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, 3. Good health, Surgery, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Internal medicine, Medicine, 030211 gastroenterology & hepatology, Anti-TNF therapy, business, Prospective cohort study, Response criteria, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

14. Macrophages from Crohn's disease patients showed a defect to control adherent-invasive Escherichia coli replication influenced by genetic host factors

Author

Buisson, A., Vazeille, Emilie, Ouchchane, L., Goutte, Marion, Hugot, J. -P., Dubois, André, Quinard, R. Minet, Bouvier, D., Bommelaer, G., Barnich, Nicolas, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Unité de biostatistique, CRLC Val d'Aurelle, Université Paris Diderot - Paris 7 (UPD7), Hôpital Ambroise Paré [AP-HP], CHU Gabriel Montpied [Clermont-Ferrand], and CHU Clermont-Ferrand

Subjects
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

15. Magnetic resonance index of activity (MaRIA) and Clermont score are two MRI indices which are highly and equally effective in detecting mucosal healing in Crohn's disease

Author

C. Allimant, Constance Hordonneau, Anthony Buisson, Gilles Bommelaer, Maud Reymond, Bruno Pereira, Marion Goutte, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Délégation à la Recherche Clinique et à l'Innovation (DRCI), Département de Radiologie (LYON - Radio), and CHU Lyon

Subjects
Crohn's disease, medicine.medical_specialty, Pathology, Index (economics), Hepatology, medicine.diagnostic_test, business.industry, Gastroenterology, Magnetic resonance imaging, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, 3. Good health, mucosal healing, 03 medical and health sciences, 0302 clinical medicine, crohn’s disease, 030220 oncology & carcinogenesis, Mucosal healing, Internal medicine, clermont score, MRI remission, medicine, 030211 gastroenterology & hepatology, business
Abstract

International audience; BACKGROUND: Magnetic resonance index of activity (MaRIA) and Clermont score are currently the two main MRI indices that have been validated compared to endoscopy in Crohn's disease (CD). AIMS: To compare the accuracy of MaRIA and Clermont score in assessing CD mucosal healing. METHODS: Fourty-four CD patients underwent prospectively and consecutively MRI and colonoscopy. RESULTS: Considering 207 segments, MaRIA>7 and Clermont score>8.4 demonstrated substantial accuracy to detect endoscopic ulcerations (73.9% and 74.0%, respectively) and presented with high specificity (82.1% and 81.3%) and high negative predictive value (NPV) (82.1% and 82.4%) for MaRIA and Clermont score, respectively. The sensitivity for detecting deep ulcerations was 90.9% for both MaRIA>11 and Clermont score>12.5, with a specificity of 82.0% and 80.0%, respectively. Among 44 patients, deep MRI remission predicted mucosal healing with specificity=85.3% and NPV=85.3% according to Barcelona criteria (no segmental MaRIA>7), and specificity=88.2% and NPV=85.7% according to Clermont criteria (no segmental Clermont score>8.4). In addition, MRI remission predicted mucosal healing with specificity=76.5% and NPV=86.7% according to Barcelona criteria (no segmental MaRIA>11), and specificity=79.4% and NPV=84.4% according to Clermont criteria (no segmental Clermont score>12.5). CONCLUSION: MaRIA and Clermont score are equally effective in detecting CD endoscopic ulcerations supporting their use as therapeutic endpoints.

Published
2017

16. Medical Therapies for Stricturing Crohn's Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic Failure

Author

Cecile Campos, Anne Dubois, Gilles Bommelaer, Constance Hordonneau, Céline Lambert, Bruno Pereira, Marion Goutte, Anthony Buisson, Michel Dapoigny, Antoine Perrey, Felix Goutorbe, Service Hépato-Gastro-Entérologie, Centre Hospitalier Universitaire de Clermont-Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Radiologie, Hospices Civils de Lyon (HCL), Unité Biostatistique, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte - Clermont Auvergne (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Service Chirurgie Digestive, MSD, Abbvie, Ferring, Takeda, Vifor Pharma, Hospira, CHU Clermont-Ferrand, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Département de Radiologie (LYON - Radio), CHU Lyon, Délégation à la Recherche Clinique et à l'Innovation (DRCI), Department of Digestive surgery, Centre Hospitalier de la Côte Basque, and Centre Hospitalier de la Côte Basque (CHCB)

Subjects
Male, Physiology, Fistula, Anti-Inflammatory Agents, Constriction, Pathologic, Anti-TNF, 0302 clinical medicine, Crohn Disease, Risk Factors, Treatment Failure, Crohn's disease, medicine.diagnostic_test, retrecissement, Hazard ratio, Gastroenterology, stenosis, Age Factors, Middle Aged, Magnetic Resonance Imaging, 3. Good health, crohn’s disease, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, Radiology, Immunosuppressive Agents, MRI, imagerie par résonance magnétique, Adult, medicine.medical_specialty, Abdominal Abscess, 03 medical and health sciences, Young Adult, Gastrointestinal Agents, Internal medicine, medicine, Intestinal Fistula, Humans, Cross-sectional imaging, Retrospective Studies, business.industry, Predictors, Tumor Necrosis Factor-alpha, Magnetic resonance imaging, Retrospective cohort study, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Odds ratio, maladie de crohn, Protective Factors, medicine.disease, Infliximab, Discontinuation, Stenosis, business, Tomography, X-Ray Computed, Stricture, thérapie, Follow-Up Studies
Abstract

International audience; BACKGROUND: Medical therapy efficacy remains controversial in stricturing Crohn's disease. Cross-sectional imaging, especially magnetic resonance imaging, has been suggested as very helpful to guide therapeutic decision making. AIM: To assess efficacy and predictors of therapeutic failure in patients receiving medical treatments for stricturing Crohn's disease. METHODS: In this retrospective study, therapeutic failure was defined as symptomatic stricture leading to surgical or endoscopic therapeutics, hospitalization, treatment discontinuation or additional therapy and short-term clinical response as clinical improvement assessed by two physicians. The 55 cross-sectional imaging examinations (33 magnetic resonance imaging and 22 CT scan) before starting medical therapy were analyzed independently by two radiologists. Results were expressed as hazard ratio (HR) or odds ratio (OR) with 95% confidence intervals (95% CI). RESULTS: Among 84 patients, therapeutic failure rate within 60 months was 66.6%. In multivariate analysis, Crohn's disease diagnosis after 40 years old (HR 3.9, 95% CI [1.37-11.2], p = 0.011), small stricture luminal diameter (HR 1.34, 95% CI [1.01-1.80], p = 0.046), increased stricture wall thickness (HR 1.23, 95% CI [1.04-1.46], p = 0.013) and fistula with abscess (HR 5.63, 95% CI [1.64-19.35], p = 0.006) were associated with therapeutic failure, while anti-TNF combotherapy (HR 0.17, 95% CI [0.40-0.71], p = 0.015) prevented it. Considering 108 therapeutic sequences, the short-term clinical response rate was 65.7%. In multivariate analysis, male gender (OR 0.15, 95% CI [0.03-0.64], p = 0.011), fistula with abscess (OR 0.09, 95% CI [0.01-0.77], p = 0.028) and comb sign (OR 0.23, 95% CI [0.005-0.97], p = 0.047) were associated with short-term clinical failure. CONCLUSION: Anti-TNF combotherapy seemed to prevent therapeutic failure, and cross-sectional imaging should be systematically performed to help medical management in stricturing Crohn's disease.

Published
2016
Full Text
View/download PDF

17. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases

Author

Gilles Bommelaer, Felix Goutorbe, Damien Bouvier, Nicolas Barnich, Emilie Vazeille, Marion Goutte, Anthony Buisson, Régine Minet-Quinard, Bruno Pereira, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA), Institut National de la Santé et de la Recherche Médicale (INSERM), Université d'Auvergne (Clermont Ferrand 1) (UdA), Département Gastroentérologie, Centre Hospitalier Universitaire Estaing, Laboratoire de Biochimie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Retinoids, Development and Developmental Diseases (R2D2), Université d'Auvergne - Clermont-Ferrand I (UdA), Service de Biostatistiques, CHU Amiens-Picardie, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte - Clermont Auvergne (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), CHU Clermont-Ferrand, ECCO European Crohn's and Colitis Organization. Vienne, AUT., and ProdInra, Migration

Subjects
Male, 0301 basic medicine, [SDV]Life Sciences [q-bio], Colonoscopy, Severity of Illness Index, Gastroenterology, Feces, 0302 clinical medicine, fluids and secretions, Crohn Disease, c-reactive protein, Intestinal mucosa, Lectins, intestinal inflammation, ulcerative-colitis, Medicine, Pharmacology (medical), Intestinal Mucosa, medicine.diagnostic_test, crohns-disease, digestive, oral, and skin physiology, Middle Aged, colonic epithelial-cells, Ulcerative colitis, 3. Good health, [SDV] Life Sciences [q-bio], chitinase, Biomarker (medicine), Female, 030211 gastroenterology & hepatology, Adult, medicine.medical_specialty, Enzyme-Linked Immunosorbent Assay, deep remission, Sensitivity and Specificity, 03 medical and health sciences, méthode endoscopique, Adipokines, Ileum, Internal medicine, Humans, Chitinase-3-Like Protein 1, Colitis, Hepatology, business.industry, activity index, ileal mucosa, Inflammatory Bowel Diseases, bacterial adhesion, medicine.disease, Faecal calprotectin, digestive system diseases, 030104 developmental biology, Colitis, Ulcerative, ustained clinical remission, Calprotectin, business, Leukocyte L1 Antigen Complex, Biomarkers, maladie inflammatoire chronique intestinale
Abstract

International audience; Background Faecal biomarkers are emerging tools in the assessment of mucosal healing in inflammatory bowel diseases (IBDs). Aim To evaluate the accuracy of faecal chitinase 3-like 1(CHI3L1) compared to calprotectin in detecting endoscopic activity in IBD. Methods Overall, 86 IBD adults underwent colonoscopy consecutively and prospectively, with Crohn's disease Endoscopic Index of Severity (CDEIS) or Mayo endoscopic subscore calculation for ulcerative colitis, and stool collection. Faecal calprotectin was measured using quantitative immunochromatographic testing. Faecal CHI3L1 was quantified by ELISA. CHI3L1 cut-off value was determined using a receiver-operating curve. Results In 54 Crohn's disease patients, faecal CHI3L1 (rho = 0.70, P < 0.001) and calprotectin (q = 0.74, P < 0.001) levels correlated with CDEIS and were significantly increased in patients with endoscopic ulceration. In patients with ileal Crohn's disease, faecal CHI3L1 seemed to be better correlated with CDEIS than faecal calprotectin (q = 0.78 vs. rho = 0.62, P < 0.001 for both). CHI3L1 > 15 ng/g detected endoscopic ulceration in Crohn's disease with a sensitivity of 100% and a specificity of 63.6%, compared to faecal calprotectin > 250 lg/g showing a sensitivity of 90.5% and a specificity of 59.1%. In 32 ulcerative colitis patients, faecal CHI3L1 and calprotectin levels correlated with Mayo endoscopic subscore (q = 0.44 and 0.61, respectively, P < 0.001 for both) and were significantly increased in ulcerative colitis patients with endoscopic activity. In ulcerative colitis patients, faecal CHI3L1 > 15 ng/g predicted endoscopic activity with a sensitivity of 81.8% and a specificity of 80.0%, compared to faecal calprotectin> 250 lg/g showing a sensitivity of 86.4% and a specificity of 80.0%. Conclusion Faecal CHI3L1 is a reliable biomarker in detecting endoscopic activity in IBD.

Published
2016
Full Text
View/download PDF

18. Endoscopy-based management decreases the risk of postoperative recurrences in Crohn's disease

Author

Anne Dubois, Anthony Buisson, Marion Goutte, Juliette Joubert, Anne-Laure Boucher, Stéphanie Decousus, Michel Dapoigny, Denis Pezet, Felix Goutorbe, Johan Gagnière, Pierre Déchelotte, Corinne Borderon, Gilles Bommelaer, Bruno Pereira, Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Université d'Auvergne - Clermont-Ferrand I (UdA), CHU Clermont-Ferrand, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA), Department of Digestive surgery, and ProdInra, Migration

Subjects
endoscopie, Male, Time Factors, crohn's disease, Disease, Kaplan-Meier Estimate, 0302 clinical medicine, Crohn Disease, Recurrence, postoperative recurrence, risk factors, Colectomy, Crohn's disease, medicine.diagnostic_test, Gastroenterology, General Medicine, Colonoscopy, Middle Aged, 3. Good health, facteur de risque, Treatment Outcome, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, France, Adult, Reoperation, medicine.medical_specialty, prevalence, Disease-Free Survival, 03 medical and health sciences, Young Adult, Predictive Value of Tests, medicine, Humans, Retrospective Cohort Study, endoscopy, Proportional Hazards Models, Retrospective Studies, prévalence, Chi-Square Distribution, business.industry, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, maladie de crohn, medicine.disease, digestive system diseases, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Endoscopy, Surgery, Hépatologie et Gastroentérologie, Multivariate Analysis, Hépatology and Gastroenterology, business
Abstract

International audience; AIM: to investigate whether an endoscopy-based management could prevent the long-term risk of postoperative recurrence. METHODS: From the pathology department database, we retrospectively retrieved the data of all the patients operated on for Crohn's disease (CD) in our center (1986-2015). Endoscopy-based management was defined as systematic postoperative colonoscopy (median time after surgery = 9.5 mo) in patients with no clinical postoperative recurrence at the time of endoscopy. RESULTS: From 205 patients who underwent surgery, 161 patients (follow-up > 6 mo) were included. Endoscopic postoperative recurrence occurred in 67.6%, 79.7%, and 95.5% of the patients, respectively 5, 10 and 20 years after surgery. The rate of clinical postoperative recurrence was 61.4%, 75.9%, and 92.5% at 5, 10 and 20 years, respectively. The rate of surgical postoperative recurrence was 19.0%, 38.9% and 64.7%, respectively, 5, 10 and 20 years after surgery. In multivariate analysis, previous intestinal resection, prior exposure to anti-TNF therapy before surgery, and fistulizing phenotype (B3) were postoperative risk factors. Previous perianal abscess/fistula (other perianal lesions excluded), were predictive of only symptomatic recurrence. In multivariate analysis, an endoscopy-based management (n = 49/161) prevented clinical (HR = 0.4, 95% CI: 0.25-0.66, p < 0.001) and surgical postoperative recurrence (HR = 0.30, 95% CI: 0.13-0.70, p = 0.006). CONCLUSION: Endoscopy-based management should be recommended in all CD patients within the first year after surgery as it highly decreases the long-term risk of clinical recurrence and reoperation.

Published
2016
Full Text
View/download PDF

19. Myenteric plexitis is a risk factor for endoscopic and clinical postoperative recurrence after ileocolonic resection in Crohn's disease

Author

Anne Dubois, Bruno Pereira, Juliette Joubert, Felix Goutorbe, Anthony Buisson, Pierre Déchelotte, Anne-Laure Boucher, Gilles Bommelaer, Stéphanie Decousus, Buisson, Anthony, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Département Gastroentérologie, CHU Clermont-Ferrand-CHU Clermont-Ferrand, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), and Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA)

Subjects
Male, Databases, Factual, crohn's disease, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Kaplan-Meier Estimate, Gastroenterology, 0302 clinical medicine, Crohn Disease, Recurrence, Risk Factors, postoperative recurrence, Postoperative Period, Young adult, Myenteric plexus, Colectomy, Crohn's disease, medicine.diagnostic_test, Anastomosis, Surgical, Middle Aged, Prognosis, 3. Good health, 030220 oncology & carcinogenesis, plexitis, Resection margin, 030211 gastroenterology & hepatology, Female, France, Adult, medicine.medical_specialty, Colon, Myenteric Plexus, 03 medical and health sciences, Young Adult, Neuritis, Ileum, Internal medicine, medicine, Humans, Risk factor, Retrospective Studies, Hepatology, business.industry, Retrospective cohort study, Endoscopy, medicine.disease, Surgery, Multivariate Analysis, business, Follow-Up Studies
Abstract

Background As surgical resection is not curative in Crohn's disease, postoperative recurrence remains a crucial issue. The selection of patients, according to available risk factors, remains disappointing in clinical practice highlighting the need for better criteria, such as histologic features. Aims To investigate whether submucosal and myenteric plexitis increase the risk of endoscopic, clinical and surgical postoperative recurrence in Crohn's disease. Methods From the pathology department database, we retrospectively retrieved the data of all the patients who have undergone ileocolonic resection for Crohn's disease. Two pathologists, blinded from clinical data, reviewed all specimens to evaluate the presence of plexitis at the proximal resection margin. Results Of the 75 included CD patients, 19 (25.3%) had histological involvement of resection margin. Inflammatory cells count for myenteric and submucosal plexus were performed in 56 patients. In multivariate analysis, the myenteric plexitis was a risk factor for endoscopic postoperative recurrence (HR 8.83 CI 95% [1.6–48.6], p = 0.012), and the presence of at least one myenteric lymphocyte (HR 4.02 CI 95% [1.4–11.2], p = 0.008) was predictive of clinical postoperative recurrence. We observed no histologic predictor for surgical postoperative recurrence. Conclusion Myenteric plexitis in proximal margins of ileocolonic resection specimens is independently associated with endoscopic and clinical postoperative recurrence in Crohn's disease.

Published
2016
Full Text
View/download PDF

20. Faecal metalloprotease 9 is a reliable biomarker compared with faecal calprotectin in detecting endoscopic activity in patients with inflammatory bowel diseases

Author

Buisson, Alain, Vazeille, Emilie, Quinard, R. M., Goutte, Marion, Bouvier, D., Goutorbe, F., Pereira, B., BARNICH, Nicolas, Bommelaer, G., Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA), Laboratoire de Biochimie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), and Institut National de la Recherche Agronomique (INRA)

Subjects
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Published
2016

21. Patients' point of view regarding acceptability and usefulness of inflammatory bowel diseases monitoring tools: results from a nationwide multicentre study (the ACCEPT study)

Author

Buisson, A., Gonzalez, F., Poullenot, F., Nancey, S., Sollellis, E., Fumery, M., Benjamin Pariente, Flamant, M., Bourreille, A., Bonnaud, G., Mathieu, S., Thevenin, A., Duruy, M., Filippi, J., L Hopital, F., Luneau, F., Michalet, V., Genss, J., Achim, A., Cruzille, E., Bommelaer, G., Laharie, D., Peyrin-Biroulet, L., Pereira, B., Nachury, M., Bouguen, G., Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Hospices Civils de Lyon (HCL), CHU Amiens-Picardie, Département de Gastroentérologie, Hôpital de l'Archet 2, Institut National de la Recherche Agronomique (INRA), CHU Bordeaux [Bordeaux], CHU Clermont-Ferrand, CHU Pontchaillou [Rennes], Service d’hépatogastroenterologie, Hôpital Claude Huriez [Lille], CHU Lille, Dept Sci Bois & Foret, Université Laval [Québec] (ULaval), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte - Clermont Auvergne (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Hôpital Claude Huriez, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Laval, Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, ComputingMilieux_MISCELLANEOUS
Abstract

International audience; Meeting Abstract: P121

Published
2016
Full Text
View/download PDF

22. A Preclinical Validation of Iron Oxide Nanoparticles for Treatment of Perianal Fistulizing Crohn's Disease.

Author

Cazelles A, Collard MK, Lalatonne Y, Doblas S, Zappa M, Labiad C, Cazals-Hatem D, Maggiori L, Treton X, Panis Y, Jarry U, Desvallées T, Eliat PA, Pineau R, Motte L, Letourneur D, Simon-Yarza T, and Ogier-Denis E

Subjects
Animals, Male, Rats, Magnetic Iron Oxide Nanoparticles, Neoplasm Recurrence, Local, Quality of Life, Rats, Sprague-Dawley, Treatment Outcome, Crohn Disease complications, Crohn Disease drug therapy, Crohn Disease pathology, Rectal Fistula drug therapy, Rectal Fistula etiology
Abstract

Fistulizing anoperineal lesions are severe complications of Crohn's disease (CD) that affect quality of life with a long-term risk of anal sphincter destruction, incontinence, permanent stoma, and anal cancer. Despite several surgical procedures, they relapse in about two-thirds of patients, mandating innovative treatments. Ultrasmall particles of iron oxide (USPIO) have been described to achieve in vivo rapid healing of deep wounds in the skin and liver of rats thanks to their nanobridging capability that could be adapted to fistula treatment. Our main purpose was to highlight preclinical data with USPIO for the treatment of perianal fistulizing CD. Twenty male Sprague Dawley rats with severe 2,4,6-trinitrobenzenesulfonic acid solution (TNBS)-induced proctitis were operated to generate two perianal fistulas per rat. At day 35, two inflammatory fistulas were obtained per rat and perineal magnetic resonance imaging (MRI) was performed. After a baseline MRI, a fistula tract was randomly drawn and topically treated either with saline or with USPIO for 1 min ( n = 17 for each). The rats underwent a perineal MRI on postoperative days (POD) 1, 4, and 7 and were sacrificed for pathological examination. The primary outcome was the filling or closure of the fistula tract, including the external or internal openings. USPIO treatment allowed the closure and/or filling of all the treated fistulas from its application until POD 7 in comparison with the control fistulas (23%). The treatment with USPIO was safe, permanently closed the fistula along its entire length, including internal and external orifices, and paved new avenues for the treatment of perianal fistulizing Crohn's disease.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results